Clinical Trial Results:
Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML19)
|
Summary
|
|
EudraCT number |
2014-002195-90 |
Trial protocol |
GB DK |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jan 2026
|
First version publication date |
29 Jan 2026
|
Other versions |
|
Summary report(s) |
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.